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a b s t r a c t
During recent years, it has become increasingly evident that donor leukemia following allogeneic
transplant may be more common then realized in the past. We identiﬁed ﬁve cases of potential donor
leukemia cases during past ﬁve years. The precise mechanism of the origin of such leukemias, however,
remains poorly deﬁned. In this short communication, we report a well documented case of donor-derived de
novo acute myeloid leukemia (AML) that developed fourteen years after allogeneic stem cell transplantation for
treatment induced AML for his primarymalignancy Immunoblastic lymphoma. This case allows us to postulate
a possible mechanism of the origin of donor leukemia. The de novo AML clone contained a distinct cytogenetic
abnormality, trisomy 11, which was simultaneously detected in preserved peripheral blood obtained at the
time of transplantation as well as in the current bone marrow from an otherwise clinically and phenotypically
normal donor. The ﬁndings from this unique case, provides insight into the process of leukemogenesis, and
suggests that the sequence of events leading to leukemogenesis in this patient involved the senescence/
apoptosis of normal donor hematopoietic cells due to telomere shortening resulting in the selective
proliferation and transformation of this clone with MLL (mixed-lineage leukemia) gene ampliﬁcation.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Donor-derived leukemias following allogeneic bone marrow trans-
plantation are rare but may offer signiﬁcant insights into the mechan-
isms of leukemogenesis. Since the ﬁrst report of donor-derived
leukemia in 1971, only 50 cases have been reported in the literature
(reviewed in Ref. 1). A number of mechanisms have been proposed to
explain donor-derived leukemogenesis including impaired immune
surveillance in the recipient, transfer of oncogenic material from
recipient to donor cells, or residual effects of conditioning chemother-
apy or radiation [1]. Inadvertent transfer of leukemic blasts from a
donor with undetected AML has also been reported. Other hemato-
logic malignancies including acute lymphoblastic leukemia, chronic
lymphocytic leukemia and non-Hodgkin lymphoma have also been
accidentally transmitted [1]. Signiﬁcantly, in these previously reported
cases, the transmission was discovered when the malignancy was
manifested in the donor [1].
We describe a novel case, wherein a patient with AML with inv
(16) underwent allogeneic bone marrow transplantation from a
related sibling donor which contained a small subpopulation of
premalignant stem cells with trisomy 11. Fourteen years following
transplantation, this patient presented with a de novo AML derived
from this inadvertently transmitted premalignant clone. Signiﬁ-
cantly, over time, this premalignant clone has remained quiescent
but persisted in the donor.
2. Methods
Conventional cytogenetics and FISH analyses were performed
employing routine methods. Donor-recipient DNA chimerism was
studied by using semiquantitative PCR with ﬂuorochrome-labeled
primers for the polymorphic microsatellite markers D7S820 and
D16S539 using the GenePrint ﬂuorescent STR multiplex system
(Promega, Madison, WI).
3. Results
A 42-year-old manwas diagnosed with Stage IIIA immunoblastic
lymphoma and treated with cyclophosphamide, doxorubicin, etopo-
side, bleomycin, vincristine, methotrexate and prednisone. He
achieved a complete remission but 17 months later developed acute
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myeloid leukemia (AML) with an inv(16)(p13q22) clonal cytogenetic
abnormality, known to be associated with AML-M4 sub-type, as the
sole abnormality detected by karyotype analysis. Standard induction
therapy with cytarabine and idarubicin was administered and the
patient achieved a complete remission. He subsequently underwent
allogeneic stem cell transplantation from his 54 year old HLA-
identical brother after conditioning with total-body irradiation,
thiotepa and cyclophosphamide. The patient achieved a sustained
complete remission. However, 14 years following transplantation,
the patient developed fatigue and easy bruising. The laboratory
ﬁndings included WBC count of 29,300/uL, 31% blasts, Hb 12.3gm/
uL and platelets 29,000/uL. Bone marrow morphologic and ﬂow
cytometric proﬁle was consistent with AML. The clonal abnormality
detected by karyotype included a 47,XY,þ11 (Fig. 1A), which was
conﬁrmed by FISH analysis (Fig. 1B). DNA chimerism assays of both
peripheral blood and bone marrow from the patient at the time of
relapse showed full donor chimerism, demonstrating that the
leukemic clone was of donor origin (Fig. 1C).
At the time of this second AML diagnosis, the donor was well
and without evidence of any hematologic disorder and normal
male karyotype. However, FISH analysis revealed trisomy 11 in 2%
of the cells analyzed (upper limit of normal o0.2%); frozen
peripheral blood from the donor stored at the time of the initial
bone marrow transplantation 14 years earlier also showed trisomy
11 in 0.4% cells (Fig. 1D).
4. Discussion
The presence of a low level of trisomy 11 in the donor's peripheral
blood from the time of donation, as well as its persistence in his bone
marrow 14 years later, suggest it was present at the time of stem cell
donation and has, to date, followed an indolent clinical course.
This unique case, wherein a genetically abnormal premalignant
clone, rather than a frankly malignant clone, was inadvertently
transmitted from the donor to the patient and which subsequently
transformed into leukemia in the recipient but not the donor. This
malignant process required a long period of latency, and this case
represents the longest reported interval from stem cell transplant
to the development of a donor-derived leukemia.
The sequence of genetic and/or epigenetic events leading to
selective proliferation and subsequent neoplastic transformation
of the clone with trisomy 11 (three copies of MLL gene) may evoke
several possibilities.
Immunodeﬁciency may facilitate the neoplastic transformation of a
premalignant clone. Primary immunodeﬁciency is well documented in
Fig. 1. Analysis of patient and donor blood and bone marrow samples. (A) A G-banded karyotype shows a 47,XY,þ11 chromosome constitution; a del(9q) was seen as a
non-clonal abnormality only in this metaphase. (B) Interphase nuclei show three copies of the MLL gene in patient's marrow at the time of AML diagnosis; MLL probe was
obtained from VYSIS, Inc (Des Plains, IL). (C) Electropherogram of semiquantitative analysis of microsatellite markers with variable tetranucleotide repeats. The peripheral
blood (mononuclear cells) of the donor is shown (Top Panel), followed by the buccal mucosa of recipient (Second panel), recipient bone marrow (Third panel) and recipient
peripheral blood (Bottom panel) at the time of diagnosis of trisomy 11 AML, conﬁrming the presence of donor hematopoietic cells with no evidence of recipient cells.
PCR primers were ﬂuorochrome-labeled and PCR products analyzed on an ABI 3730 automated DNA sequence analyser (PE Biosystems, Foster City, CA). Please note that a
smaller peak (indicated by Red arrow) detected in donor mononuclear cells is due to overloading of the sample, as the marker D7S820 consists of only one speciﬁc allele.
(D) Interphase nucleus to show three copies of the MLL gene in donor peripheral blood sample collected at the time of transplantation 14 years earlier.
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patients with ataxia-telangiectasia (AT) and Bloom's Syndrome (BS)
and such immune deﬁcient states are known to permit clonal
expansion of cells with underlying mutations in the lymphoid and
myeloid systems respectively [2]. The primary immunodeﬁciency as a
contributory factor in the development of donor leukemia in the
patient is unlikely. Secondary immunodeﬁciency due to chemotherapy
and radiation administered is likely a possibility in leukemia arising
following autologous stem cell transplantation with short latency
period, but highly unlikely in this case given the long latency period
of fourteen years in this case.
We suggest, alternatively, that premature senescence and or
programmed cell death of the normal transplanted donor stem cells
due to telomere erosion may have played a role (Fig. 2). The difference
in telomere dynamics between normal donor cells and donor cells
with trisomy 11 may contribute signiﬁcantly to the selective prolifera-
tion and neoplastic transformation of the latter. In fact, Notaro et al.
(1997) [3] previously found that telomere length of engrafted donor
cells was signiﬁcantly reduced when compared to donor cells,
suggesting that telomere shortening may reduce the proliferative
potential of the engrafted donor cells. In addition, it is also well
recognized that telomere erosion also results in a signiﬁcant genomic
instability, the hall mark of malignant transformation [4]. It is
furthermore known that following allogeneic stem cell transplanta-
tion, the reduction in telomere length of donor hematopoietic cells is
equivalent to approximately 15 years, and in some instances 40–60
years, of aging [5,6]. Several studies suggest that the reduction in
telomere length, which occurs predominantly during the ﬁrst year
following transplantation, is unlikely to signiﬁcantly compromise bone
marrow function. However, it is important to recognize that such data
is largely derived from a younger donor and recipient population
(ageo40) [7]. It is therefore conceivable that in the present case, with
an older donor (54 at the time of stem collection), this well recognized
reduction in telomere length may have compounded the overall effect
of this phenomenon. Therefore, normal stem cells from an older donor
are placed under replicative stress, which in turn may reduce the
proliferative capacity of these cells [3]. The resulting senescence of
normal donor hematopoietic cells over the 14 years following trans-
plantation in our patient may have set the stage for the expansion of
cells with trisomy 11. The ampliﬁcation of MLL protein in these, now
dividing cells may have triggered a cascade of events leading to frank
leukemia [8]. Several studies reviewed elsewhere have suggested that
ampliﬁcation of MLL gene may activate HOX genes which are known
to play important role in leukemogenesis [8].
Lastly, it is equally important to mention that the microenvir-
onment and genetic background of the host with a previous
history of two independent malignancies may have further facili-
tated the selective proliferation of a clone with trisomy 11 [9,10],
while normal cells suffered proliferative stress resulting in senes-
cence or apoptosis.
We, therefore, propose that the sequence of genetic and
epigenetic events leading to leukemogenesis of donor cells with
trisomy 11 includes telomere shortening in normal donor derived
hematopoietic stem cells due to excessive stress to reconstitute
host hematopoietic compartment, results in selective proliferation
of a clone with MLL ampliﬁcation, which in turn activated genes
such as HOX, known to be deregulated in MDS and AML [8].
Donor-derived leukemia holds promise as a method to study
in vivo leukemogenesis, in both allogeneic and autologous transplants.
Fig. 2. A proposed mechanism whereby a pre-malignant donor clone containing the trisomy 11 cytogenetic abnormality transferred into the patient at the time of an
allogeneic bone marrow transplantation evolved into a frankly malignant AML clone over 14 years following transplantation. In the recipient, rapid telomere erosion in
normal donor stem cells following transplantation results over time (14 years) in selective growth advantage of the clone with trisomy 11 and subsequent transformation to a
true malignant clone due to activation of HOX genes and possibly other genetic/epigenetic events not fully recognized, as additional cells and DNA sample were not available
for molecular studies. In the donor, a lack of dramatic telomere shortening in normal stem cells explains the persistent but quiescent nature of the trisomy 11 clone.
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This unusual case provides new insight into this process. It suggests
that genetic abnormalities which ultimately lead to leukemia may be
latent for long periods of time. Although uncommon, donor-derived
leukemia incidence may not be exceptionally rare and perhaps is
under-reported. Multi-institutional prospective studies should be
considered in cases of leukemic relapse after stem cell transplantation
to investigate the underlying genetic/epigenetic molecular mechanism
(s) of donor leukemia to support or refute our hypothesis of
leukemogenesis.
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